Šalis: Jungtinės Valstijos
kalba: anglų
Šaltinis: NLM (National Library of Medicine)
CICLESONIDE (UNII: S59502J185) (CICLESONIDE - UNII:S59502J185)
Prasco Laboratories
RESPIRATORY (INHALATION)
PRESCRIPTION DRUG
Ciclesonide Inhalation Aerosol is indicated for the maintenance treatment of asthma as prophylactic therapy in adult and adolescent patients 12 years of age and older. Important Limitations of Use: Ciclesonide Inhalation Aerosol is NOT indicated for the relief of acute bronchospasm. Ciclesonide Inhalation Aerosol is NOT indicated for children under 12 years of age. Ciclesonide Inhalation Aerosol is contraindicated in the primary treatment of status asthmaticus or other acute episodes of asthma where intensive measures are required. Ciclesonide Inhalation Aerosol is contraindicated in patients with known hypersensitivity to ciclesonide or any of the ingredients of Ciclesonide Inhalation Aerosol. Rare cases of hypersensitivity reactions with manifestations such as angioedema, with swelling of the lips, tongue and pharynx, have been reported. Teratogenic Effects : Pregnancy Category C Oral administration of ciclesonide in rats up to 900 mcg/kg/day (approximately 10 times the maximum human daily inhalation dose
Ciclesonide Inhalation Aerosol is available in the following strengths and canister presentations. Micrograms per Actuation Number of Actuations per Canister Canister Weight Canister per Box NDC Number Ciclesonide Inhalation Aerosol 80 mcg Inhalation Aerosol is supplied with a brown plastic actuator with a red dust cap. Each actuation of the inhaler delivers 80 mcg of ciclesonide from the actuator. Ciclesonide Inhalation Aerosol 160 mcg Inhalation Aerosol is supplied with a red plastic actuator with a red dust cap. Each actuation of the inhaler delivers 160 mcg of ciclesonide from the actuator. Ciclesonide Inhalation Aerosol canisters are for use with Ciclesonide Inhalation Aerosol Inhalation Aerosol actuators only. The actuators are fitted with a dose indicator and should not be used with other inhalation aerosol medications. The correct amount of medication in each actuation cannot be assured from the canister labeled to contain 60 actuations when the dose indicator display window shows zero even though the canister is not completely empty. The canister should be discarded when the dose indicator display window shows zero. Store at 25°C (77°F). Excursions between 15° and 30°C (59° and 86°F) are permitted (see USP). For optimal results, the canister should be at room temperature when used. Keep out of reach of children. CONTENTS UNDER PRESSURE Do not puncture. Do not use or store near heat or open flame. Exposure to temperatures above 49°C (120°F) may cause bursting. Never throw canister into fire or incinerator.
New Drug Application Authorized Generic
CICLESONIDE- CICLESONIDE AEROSOL, METERED PRASCO LABORATORIES ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE CICLESONIDE INHALATION AEROSOL SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR CICLESONIDE INHALATION AEROSOL. CICLESONIDE INHALATION AEROSOL 80 MCG, 160 MCG FOR ORAL INHALATION ONLY INITIAL U.S. APPROVAL: 2006 INDICATIONS AND USAGE Ciclesonide Inhalation Aerosol is an inhaled corticosteroid indicated for: Maintenance treatment of asthma as prophylactic therapy in adult and adolescent patients 12 years of age and older. (1) Ciclesonide Inhalation Aerosol is NOT indicated for the relief of acute bronchospasm. (1) DOSAGE AND ADMINISTRATION FOR ORAL INHALATION ONLY (2) RECOMMENDED STARTING DOSE HIGHEST RECOMMENDED DOSE Patients ≥ 12 years who received bronchodilators alone 80 mcg twice daily 160 mcg twice daily Patients ≥ 12 years who received inhaled corticosteroids 80 mcg twice daily 320 mcg twice daily Patients ≥ 12 years who received oral corticosteroids 320 mcg twice daily 320 mcg twice daily Prednisone should be reduced gradually, no faster than 2.5 mg/day on a weekly basis, beginning after at least 1 week of therapy with Ciclesonide Inhalation Aerosol. Patients should be carefully monitored for signs of asthma instability, including monitoring of serial objective measures of airflow, and for signs of adrenal insufficiency during steroid taper and following discontinuation of oral corticosteroid therapy [_see_ _Warnings and Precautions_ (5.1)]. DOSAGE FORMS AND STRENGTHS Inhalation Aerosol 80 mcg/actuation or 160 mcg/actuation (3) CONTRAINDICATIONS Patients with status asthmaticus or other acute episodes of asthma where intensive measures are required. (4.1) Patients with a known hypersensitivity to ciclesonide or any of the ingredients of Ciclesonide Inhalation Aerosol. (4.2) WARNINGS AND PRECAUTIONS _Candida albicans_ infection of the mouth and pharynx. Monitor patients periodically for signs of adverse effects on t Perskaitykite visą dokumentą